Search results

1. GSK and Hansoh press on despite Pfizer’s exit

   … AstraZeneca ADC Ph1/2 underwhelmed at ESMO 2024, with ORR 25% in ≥25% expressers …

   
    

   Madeleine Armstrong
    
   - 03/06/2025 - 13:28

2. Bristol exits KRAS G12D

   … Astellas Degrader Lacklustre ph1 data at ESMO 2024; proof-of-concept judgement due in H1 2025 …

   
    

   Madeleine Armstrong
    
   - 03/06/2025 - 13:30

3. The month ahead: March's upcoming events

   … dosing in Jul 2024; 8 treatment-related deaths reported at ESMO 2024 Source: OncologyPipeline.   …

   
    

   Jacob Plieth
    
   - 03/21/2025 - 08:31

4. Regeneron’s Met bet falls short

   … x Met bispecific MAb Ph1/2 in Met-altered NSCLC ESMO 2024: ORR 12% (9/74) in pts receiving 2000mg …

   
    

   Madeleine Armstrong
    
   - 04/16/2025 - 15:49

5. What future for Lag3 blockade?

   … Ph2 chemo combo, failed on PFS vs Opdivo + chemo at ESMO 2024; numerical benefit in post-hoc non-sq 1-49% PD-L1 …

   
    

   Jacob Plieth
    
   - 02/18/2025 - 15:54

6. The month ahead: February’s upcoming events

   … dosing in Jul 2024; 8 treatment-related deaths reported at ESMO 2024 Source: OncologyPipeline. …

   
    

   Madeleine Armstrong
    
   - 02/04/2025 - 16:15

7. Daiichi ups its Glycotope bet

   … None Ph1 in Claudin6+ve solid tumours; initial data at ESMO 2024: Source: OncologyPipeline. …

   
    

   Madeleine Armstrong
    
   - 01/16/2025 - 13:06

8. I-Mab bets on a Bristol buy-in

   … Givastomig Claudin18.2 x 4-1BB Ph1 monoRx data at ESMO 2024; Opdivo + chemo combo data (BMS clinical trial …

   
    

   Jacob Plieth
    
   - 01/07/2025 - 15:45

9. The month ahead: January’s upcoming events

   … dosing in Jul 2024; 8 treatment-related deaths reported at ESMO 2024 Source: OncologyPipeline. …

   
    

   Madeleine Armstrong
    
   - 01/02/2025 - 17:41

10. Cabometyx’s Cabinet committee

    … 3 April PDUFA date.   Source: Dr Jennifer Chan & ESMO 2024. Regulatory …

    
     

    Madeleine Armstrong
     
    - 11/28/2024 - 14:33